PL2534149T3 - Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu - Google Patents

Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu

Info

Publication number
PL2534149T3
PL2534149T3 PL11709025T PL11709025T PL2534149T3 PL 2534149 T3 PL2534149 T3 PL 2534149T3 PL 11709025 T PL11709025 T PL 11709025T PL 11709025 T PL11709025 T PL 11709025T PL 2534149 T3 PL2534149 T3 PL 2534149T3
Authority
PL
Poland
Prior art keywords
purin
methylbutyl
piperidinyl
maleate
dihydro
Prior art date
Application number
PL11709025T
Other languages
English (en)
Polish (pl)
Inventor
Robert Hermann Gibbon
Amanda Lucas
Stephen Andrew Hermitage
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PL2534149T3 publication Critical patent/PL2534149T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
PL11709025T 2010-02-10 2011-02-08 Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu PL2534149T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30301010P 2010-02-10 2010-02-10
PCT/EP2011/051830 WO2011098452A1 (en) 2010-02-10 2011-02-08 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
EP11709025.8A EP2534149B1 (en) 2010-02-10 2011-02-08 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate

Publications (1)

Publication Number Publication Date
PL2534149T3 true PL2534149T3 (pl) 2015-03-31

Family

ID=43836817

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11709025T PL2534149T3 (pl) 2010-02-10 2011-02-08 Maleinian 6-amino-2-{[(1s)-1-metylobutylo]oksy}-9-[5-(1-piperydynylo)pentylo]-7,9-dihydro-8h-puryn-8-onu

Country Status (23)

Country Link
US (1) US8703754B2 (OSRAM)
EP (1) EP2534149B1 (OSRAM)
JP (1) JP5922587B2 (OSRAM)
KR (1) KR101773541B1 (OSRAM)
CN (1) CN102753553B (OSRAM)
AU (1) AU2011214468B2 (OSRAM)
BR (1) BR112012018904A2 (OSRAM)
CA (1) CA2786973C (OSRAM)
DK (1) DK2534149T3 (OSRAM)
EA (1) EA021048B1 (OSRAM)
ES (1) ES2525826T3 (OSRAM)
HR (1) HRP20141258T1 (OSRAM)
IL (1) IL220845A (OSRAM)
ME (1) ME01926B (OSRAM)
MX (1) MX2012009316A (OSRAM)
PL (1) PL2534149T3 (OSRAM)
PT (1) PT2534149E (OSRAM)
RS (1) RS53745B1 (OSRAM)
SG (1) SG182471A1 (OSRAM)
SI (1) SI2534149T1 (OSRAM)
SM (1) SMT201400196B (OSRAM)
WO (1) WO2011098452A1 (OSRAM)
ZA (1) ZA201205995B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
CA2777824C (en) 2009-10-22 2016-11-29 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
LT2734186T (lt) * 2011-07-22 2018-12-10 Glaxosmithkline Llc Kompozicija
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CA2879066C (en) * 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
MX359671B (es) 2012-08-24 2018-10-05 Glaxosmithkline Llc Star Compuestos de pirazolopiridina.
JP6228223B2 (ja) 2012-11-20 2017-11-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 新規化合物
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
RU2643371C2 (ru) 2012-11-20 2018-02-01 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
WO2016033540A1 (en) * 2014-08-29 2016-03-03 Corium International, Inc. Microstructure array for delivery of active agents
US10584125B2 (en) * 2014-11-13 2020-03-10 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US12130267B2 (en) * 2018-11-28 2024-10-29 Shimadzu Corporation Analyzing method for azo compound
KR20250106231A (ko) 2023-12-29 2025-07-09 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
NZ263686A (en) 1993-03-17 1997-09-22 Minnesota Mining & Mfg Medicinal aerosol with dispersing aid derived from a hydroxy acid, an amino acid and/or a mercapto acid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1065213A3 (en) 1999-07-02 2003-11-05 Japan Tobacco Inc. HCV polymerase suitable for crystal structure analysis and method for using the enzyme
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
HUP0400726A3 (en) 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
CA2448737C (en) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1497469A4 (en) 2002-04-04 2005-06-08 Achillion Pharmaceuticals Inc TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
WO2004037818A1 (en) 2002-10-24 2004-05-06 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
ES2311755T3 (es) 2002-12-13 2009-02-16 Smithkline Beecham Corporation Compuestos de ciclohexilo como antagonistas de ccrs.
AU2003300952A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
ES2298627T3 (es) 2002-12-13 2008-05-16 Smithkline Beecham Corporation Compuestos de ciclopropilo como antagonistas de ccr5.
DE60322423D1 (de) 2002-12-13 2008-09-04 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
ES2312856T3 (es) 2002-12-13 2009-03-01 Smithkline Beecham Corporation Compuestos heterociclicos como antagonistas de ccr5.
CN1744899A (zh) 2002-12-13 2006-03-08 史密丝克莱恩比彻姆公司 作为ccr5拮抗剂的哌啶衍生物
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
CN102028994B (zh) 2003-11-03 2013-04-24 葛兰素集团有限公司 流体分配装置
IN2012DN04853A (OSRAM) 2004-02-20 2015-09-25 Boehringer Ingelheim Int
EP1748991A1 (en) 2004-04-28 2007-02-07 Arrow Therapeutics Limited Morpholinylanilinoquinazo- line derivatives for use as antiviral agents
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2577525C (en) 2004-08-18 2010-03-30 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
US20060045885A1 (en) 2004-08-27 2006-03-02 Kedl Ross M Method of eliciting an immune response against HIV
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
KR20080019213A (ko) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 티아졸 화합물 및 그 사용방법
EP1939198A4 (en) * 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
GB0610666D0 (en) 2006-05-30 2006-07-05 Glaxo Group Ltd Fluid dispenser
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
WO2008114008A1 (en) * 2007-03-19 2008-09-25 Astrazeneca Ab 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators
PE20091156A1 (es) * 2007-12-17 2009-09-03 Astrazeneca Ab Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo
US8777708B2 (en) 2008-06-27 2014-07-15 Microsoft Corporation Targeting control in a simulated environment
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань

Also Published As

Publication number Publication date
AU2011214468B2 (en) 2015-05-28
PT2534149E (pt) 2014-12-23
SG182471A1 (en) 2012-08-30
EP2534149B1 (en) 2014-10-15
HRP20141258T1 (hr) 2015-02-27
RS53745B1 (sr) 2015-06-30
CA2786973A1 (en) 2011-08-18
EA201290631A1 (ru) 2013-03-29
KR101773541B1 (ko) 2017-08-31
SI2534149T1 (sl) 2015-02-27
DK2534149T3 (da) 2015-01-05
CN102753553A (zh) 2012-10-24
US8703754B2 (en) 2014-04-22
IL220845A (en) 2016-08-31
WO2011098452A1 (en) 2011-08-18
ZA201205995B (en) 2014-01-29
JP2013519645A (ja) 2013-05-30
CA2786973C (en) 2018-04-10
SMT201400196B (it) 2015-01-15
ES2525826T3 (es) 2014-12-30
MX2012009316A (es) 2012-09-12
BR112012018904A2 (pt) 2020-09-01
EP2534149A1 (en) 2012-12-19
US20120308609A1 (en) 2012-12-06
CN102753553B (zh) 2016-03-30
ME01926B (me) 2015-05-20
EA021048B1 (ru) 2015-03-31
JP5922587B2 (ja) 2016-05-24
AU2011214468A1 (en) 2012-08-09
KR20120135408A (ko) 2012-12-13

Similar Documents

Publication Publication Date Title
IL220845A (en) 6-amino-2 - {[(1 s) –1– methylbutyl] oxy} –9– [5– (1-piperidinyl) pentyl] –9,7 – dihydro-8 h– purine-8 – and malt
EP2624698A4 (en) Furo [3,2-D] PYRIMIDINE COMPOUNDS
IL237471A (en) Annals of [[(s1) –2– isopropoxy – 1 – methyl – 2 – oxo-ethyl] amino] –phenoxy – phosphoryl
EP2589897A4 (en) Touch-control multifunctional refrigerating cup holder
ZA201105352B (en) Novel benzodiazepine derivatives
EP2507763A4 (en) LOCATION BASED SEARCH
WO2011163332A9 (en) Methods for detecting cancer
GB0904171D0 (en) Cyclonic separator
SI2473053T1 (sl) Substiturani derivati ksantina
EP2524552A4 (en) Wireless sensor synchronization methods
ZA201209029B (en) Novel pyrimidine derivatives
IL233282A0 (en) Manufacturing process for pyrimidine history
EP2408303A4 (en) MORPHINANE DERIVATIVES HAVING HIGH ORAL BIOLOGICAL AVAILABILITY
ZA201204429B (en) Ethynyl derivatives
EP2616477A4 (en) 6-SUBSTITUTED DEMETHYL-ESTRADIOL DERIVATIVES AS ER-BETA AGONISTS
IL212942A0 (en) Rifamycin derivatives
IL220307A0 (en) New secondary 8-hydroxyquinoline-7-carboxamide derivatives
AU2009904914A0 (en) Clothing for infants
AU2013204145B2 (en) Pure erlotinib
AU2010901004A0 (en) Garment for ostymates
GB0902733D0 (en) Complex pants
AU2008905196A0 (en) Clothing for infants
AU2009905082A0 (en) Multi-Purpose Garment
HK1157151B (en) Garment
AU2009902860A0 (en) Garment